Theears FY 2025 Annual ReportBeta
Theears annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 19, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Theears FY 2025 Annual Report Analysis
Business Overview
- • 2025 revenue mix: 89.03% from thynC™ inpatient monitoring, 10.36% from mobiCARE™ ECG diagnostic solution
- • thynC™ launched officially in 2024, cumulative installation over 12,000 hospital beds by 2025
Management Discussion & Analysis
- • Revenue KRW 48.17B (+494.72% YoY); Operating profit KRW 16.33B (turnaround from KRW -8.68B); Net income KRW 16.05B (turnaround from KRW -8.87B)
- • thynC™ segment revenue KRW 42.9B, 10x growth YoY driven by EX871 remote heart monitoring fee adoption and hospital demand increase
Risk Factors
- • FX exposure includes multiple foreign currencies with sensitivity to exchange rate fluctuations; no specific KRW impact quantified
- • No new derivative contracts or putback options held as of FY2025 reporting date
Theears FY 2025 Key Financial MetricsDART
Total Assets
KRW 54.2B
▲ +93.0% YoY
Operating Cash Flow
KRW 2.1B
▲ +118.8% YoY
CapEx
KRW 1.5B
▲ +272.4% YoY
Source: KIFRS consolidated financial data from Theears annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding